Effect of a Fibrate and a Statin on Endothelial Dysfunction

Exclusion Criteria

• •Change in therapy for glucose control or blood pressure less than 1 month before entry
• •Hemoglobin A1C greater than 8.0%.
• •Renal insufficiency (serum creatinine greater than 1.6 mg/dl in men or 1.5 mg/dl in women.
• •Any investigational drug less than 1 month before entry.
• •Pregnancy (excluded by urine pregnancy test at study entry with ongoing use of reliable form of birth control) or lactation
• •Liver function tests or serum creatinine kinase (CK) greater than 3 times upper limit of normal.
• •Clinically evident major illnesses or other problem that would make participation inappropriate
• •Clinical history of symptomatic cholelithiasis
• •Patients with coronary artery disease, peripheral arterial disease, or cerebral vascular disease will not be enrolled if they are currently taking lipid-lowering therapy
• •Patients taking more than 40 mg/day of atorvastatin will be excluded. There is no "ceiling" level for patients taking fibrates.